Symphogen gains US patent for development of symphobodies  

2005.02.24
Denmark's Symphogen has been granted a US patent for development of combinant polyclonal antibodies, known as symphobodies, to treat and prevent allergic reactions

Biotech company Symphogen based in Copenhagen, has been granted a US patent for development of recombinant polyclonal antibodies, known as symphobodies, to treat and prevent allergic reactions. Dr. Kirsten Drejer, CEO of Symphogen, says the product patent is an important milestone as it highlights the company's improved therapeutic compositions comprising human antibodies, and positions it to enter the allergy market. The news is reported by professional journal Ingeniøren (the Engineer).

 

Symphogen A/S pioneers therapeutic products based on recombinant natural human antibodies for the treatment and prevention of human disease. Symphobodies offer a number of advantages over current plasma-derived immunoglobulins and monoclonal antibody therapies for the treatment of infectious diseases, allergy, transplant rejection and cancer. Collectively, Symphogen’s technologies offer best in class antibody therapeutics against both simple and complex target antigens. The commercial potential of symphobodies is expected to be very significant.

 

Link > Symphogen 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×